• Ayyappan P
  • Sahana C
  • Poovizhi S
  • Sivasakthi K



Objectives: Cardiovascular disease (CVD) is one of the leading killer diseases of people around the world. The purpose of this study was to examine the CVD risk factor and perception among individuals with high CVD risk.

Methods: An observational study was conducted for 6 months in the Department of General Medicine of a Multi-Specialty Hospital. Patients who were hypertensive, diabetic, and dyslipidemia with/without comorbid disease were included. Patients who are seriously ill, mentally retarded, physical disabilities, history of CVD, etc., were excluded. CVD risk assessment was done using Framingham risk score, and knowledge assessment was done using knowledge questionnaire on CVD risk. Patient counseling was given to the patients based on their risk and knowledge level and also to improve knowledge about CVD risk and therapeutic goals for the control of blood pressure, blood glucose, lipid profile, and smoking cessation.

Results: A total of 100 patients were included in this study comprising 46 males and 54 female. Male has more risk than female. The factors, viz., age, smoking habits, high cholesterol, and diabetes mellitus showed a greater risk in CVD. Knowledge levels assessed in those patients are 28% patients having poor knowledge, 30% patients having fair knowledge, and 42% patients having good knowledge.

Conclusion: The study concluded that the participants showed poor knowledge in CVD, which could turn into insufficient preventative behaviors and suboptimal patient outcomes. Pharmacist implementation is needed to assess CVD risk and to improve the health-related quality of life.

Keywords: Cardiovascular disease risk, Framingham risk score, Knowledge questionnaire.


Download data is not yet available.

Author Biography





Priya JK, Balambigai MS, Sariga N, Sathya M, Andhuvan G. Development and validation of patient information leaflet for heart attack patients. Int J Pharm Pharm Sci 2016;8(8):381‑3.

Kounelis AP. Pharmacists Role in Cardiovascular Disease Management ‑ 13 August; 2015. Available from: http://www.‑pharmacist’s‑role‑in‑ cardiovascular‑disease‑risk‑management.aspx#.VgD‑hN‑qqko.

Fall T, Hägg S, Ploner A, Mägi R, Fischer K, Draisma HH, et al. Age ‑ And sex‑specific causal effects of adiposity on cardiovascular risk factors. Diabetes 2015;64:1841‑52.

Andhuvan G, Venkatachalam VV, Sankar V. Impact of pharmacist education on medication adherance in heart failure patients. Int J Pharm Pharm Sci 2014;6(11):474‑6.

Awad A, Al‑Nafisi H. Public knowledge of cardiovascular disease and its risk factors in Kuwait: A cross‑sectional survey. BMC Public Health 2014;14:1131.

D’Agostino RB Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: Insights from Framingham. Glob Heart 2013;8(1):11‑23.

Altowaijri A, Phillips CJ, Fitzsimmons D. A systematic review of clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. J Manag Care Pharm 2013;19(5):405‑16.

IANS. Modified: World Health Day 2014: Is India staring at a heart disease epidemic? Diabetes Care 2012;35:334‑41.

Talasaz AH. The potential role of clinical pharmacy services in patients with cardiovascular diseases. J Tehran Univ Heart Cent 2012;7(2):41‑6.

Mullie P, Clarys P. Association between cardiovascular disease risk factor knowledge and lifestyle. Food Nutr Sci 2011;2(10):1048‑53.

Bitton A, Gaziano TA. The Framingham Heart Study’s impact on global risk assessment. Prog Cardiovasc Dis 2010;53(1):68‑78

Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: A systematic review. Diabetolgia 2009;52(10):2001‑14.

Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: A systematic review and meta‑analysis of randomized trials. Arch Intern Med 2011;171(16):1441‑53.

Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D’Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care 2008;31(8):1582‑4.

Eriksson KM, Westborg CJ, Eliasson MC. A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. Scand J Public Health 2006;34(5):453‑61.

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten‑year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24(11):987‑1003.

D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286(2):180‑7.

Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple‑risk‑factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999;34(4):1348‑59.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837‑47.



How to Cite

G, A., A. P, S. C, P. S, and S. K. “KNOWLEDGE OF MODIFIABLE RISK FACTORS OF HEART DISEASE AMONG PATIENTS WITH CARDIOVASCULAR RISK”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 1, Jan. 2017, pp. 99-102, doi:10.22159/ajpcr.2017.v10i1.14180.



Original Article(s)